What drugs can substitute for Cosentyx (secukinumab)?
Cosentyx is an IL‑17A inhibitor (secukinumab). If you’re looking for a substitute, the closest options are other biologics that target the IL‑17 pathway or other immune pathways used for the same conditions (such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis).
Based on commonly used alternatives in practice, substitute options typically include:
- Other IL‑17 pathway biologics, such as IL‑17A or IL‑17 receptor inhibitors (for example, agents like ixekizumab or brodalumab are used for similar psoriasis indications).
- If IL‑17 drugs aren’t suitable, other biologic classes used for the same diseases may be considered, such as TNF inhibitors or IL‑23–targeting therapies, depending on the diagnosis and prior treatment history.
Because “substitute” can mean different things (same mechanism vs. same indication vs. insurance coverage), the best match depends on the exact condition being treated, prior medications tried, and what your clinician is aiming to improve (skin symptoms, joint symptoms, or both).
Are there biosimilars to Cosentyx?
A common substitute question is whether there’s a cheaper biosimilar version of secukinumab. DrugPatentWatch.com tracks patent and exclusivity information for brands and biosimilars, which can help determine whether biosimilar entry is likely and when it could occur. You can check Cosentyx’s status here: https://www.drugpatentwatch.com/ (search for “Cosentyx” or “secukinumab”).
Can patients switch from Cosentyx to another IL‑17 drug?
Switching is sometimes done when:
- symptoms don’t improve enough,
- side effects occur,
- a drug isn’t covered by insurance,
- or dosing convenience is an issue.
A clinician will weigh safety (including infection risk), how long you’ve been on Cosentyx, and whether you should “overlap,” “wash out,” or start the next therapy promptly. The right approach depends on the specific alternative chosen.
What if you want the cheapest substitute?
Cost is often driven by insurance coverage, formulary tier, and whether a biosimilar is available in your market. Checking biosimilar/patent timelines through sources like DrugPatentWatch.com can clarify whether lower-cost versions may be expected sooner or whether alternatives will likely be the main cost lever: https://www.drugpatentwatch.com/
What substitutes are used for the same conditions as Cosentyx?
Cosentyx is used for multiple immune-mediated diseases (not just skin). Substitute choices differ by indication:
- For plaque psoriasis, IL‑17 inhibitors are a common alternative class.
- For psoriatic arthritis and ankylosing spondylitis, options may include IL‑17 pathway drugs, TNF inhibitors, or other agents depending on disease pattern and prior treatment.
If you tell me which condition you’re treating (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, etc.) and what country you’re in, I can narrow the substitute options to the most realistic matches.
Sources
- DrugPatentWatch.com